ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Vivoryon Therapeut

Vivoryon Therapeut (VVY)

2,14
0,06
(2,88%)
Fermé 14 Septembre 5:30PM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
2,14
Prix Achat
2,07
Prix Vente
2,165
Volume échangé
382 147
2,03 Fourchette du Jour 2,21
0,41 Plage de 52 semaines 20,77
Cap du marché
Clôture Veille
2,08
Ouverture
2,11
Dernière Transaction
1
@
2.14
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
733 034
Actions en circulation
0,00
Rendement du Dividende
-
Ratio Cours sur Bénéfices
0,00
Bénéfice par action (BPA)
-
Chiffre d'affairess
-3,62M
Bénéfice net
-28,34M

À propos de Vivoryon Therapeut

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
Siège social
Halle, Deu
Fondé
-
Vivoryon Therapeut est coté dans le secteur Biological Pds,ex Diagnstics de la Euronext avec le ticker VVY. Le dernier cours de clôture d'Vivoryon Therapeut était de 2,08 €. Au cours de la dernière année, les actions de Vivoryon Therapeut ont été négociées dans une fourchette de prix de 0,41 € à 20,77 €.

Vivoryon Therapeut compte actuellement 0 actions en circulation.

VVY Dernières nouvelles

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Halle (Saale) / Munich, Germany, July 9, 2024 - Vivoryon Therapeutics N.V. (Euronext...

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21...

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New...

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress...

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Halle (Saale) / Munich...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.1-4.464285714292.242.391.8241438622.09797236DE
40.0753.631961259082.0652.881.3243525802.14984082DE
121.488228.2208588960.6526.30.417330342.08055233DE
26-9.6-81.771720613311.7412.860.415182622.24170148DE
52-18.56-89.661835748820.720.770.412159234.13321094DE
156-4.26-66.56256.423.250.411662795.33524291DE
2600002.22000DE

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MLSUMSumo Resourcs Plc
0,0095 €
(111,11%)
10k
ARTOArtois
9 400,00 €
(70,91%)
38
ALAGOEPango SA
0,272 €
(60,00%)
3,08M
ALQGCQuantum Genomics
0,0162 €
(52,83%)
4,02M
FMONCMoncey Fin Nom
11 900,00 €
(42,51%)
198
MLIMLImalliance
0,28 €
(-25,93%)
194
MLMAZMazaro NV
3,00 €
(-25,00%)
16
MLFTIFrance Tourisme Immobilier
0,033 €
(-23,26%)
33,7k
MLSMLSmalto
0,016 €
(-20,00%)
1,58k
ALPCVCerinnov Group
1,19 €
(-18,77%)
136,64k
ALTDTonner Drones
0,0136 €
(-15,00%)
58,02M
ALCYBCybergun
0,0001 €
(0,00%)
57,02M
BCPBanco Comercial Portugues SA
0,413 €
(1,18%)
50,34M
LOCALSolocal Groupe
0,0029 €
(3,57%)
27,63M
ALDRVDrone Volt
0,0048 €
(-2,04%)
20,04M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock